Insight Molecular Diagnostics
IMDX
25 hedge funds and large institutions have $12.8M invested in Insight Molecular Diagnostics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 2 closing their positions.
12% more capital invested
Capital invested by funds: $11.4M → $12.8M (+$1.39M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
2.47% less ownership
Funds ownership: 55.37% → 52.9% (-2.5%)
4% less funds holding
Funds holding: 26 → 25 (-1)
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.94K |
| 2 |
NS
NBC Securities
Birmingham,
Alabama
|
+$463 |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$40 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$379K |
| 2 |
PVI
Pura Vida Investments
New York
|
-$195K |
| 3 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$48.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.48K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
RhumbLine Advisers
Boston,
Massachusetts
| – | -$204 | -66 | Closed |
|
|
LC
27
Lindbrook Capital
Calabasas,
California
| – | -$10 | -4 | Closed |
|
IMDX Hedge Fund Activity: Q1 2024 in Review
25 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2024, worth a combined $12.8M — up 12% from $11.4M a quarter earlier.
Fund positioning in IMDX was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 9 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $2.94K. The largest seller was Morgan Stanley, cutting an estimated $379K.
- 25 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2024, down from 26 in Q4 2023.
- Funds reported $12.8M of Insight Molecular Diagnostics stock for Q1 2024, up 12% quarter-over-quarter.
- 2 funds opened new Insight Molecular Diagnostics positions in Q1 2024 and 2 closed out, a net change of 0 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2024 was Geode Capital Management, an estimated $2.94K added.
- The largest Insight Molecular Diagnostics seller in Q1 2024 was Morgan Stanley, an estimated $379K sold.
Based on aggregated 13F filings for Q1 2024.